Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents

Inflammatory Bowel Diseases

Volumn 18, Issue 11, 2012, Pages 2011-2017

  Molander, Pauliina ^a,b   Af Björkesten, Clas Göran ^b   Mustonen, Harri ^b   Haapamäki, Johanna ^b   Vauhkonen, Matti ^b   Kolho, Kaija Leena ^c   Färkkilä, Martti ^a,b   Sipponen, Taina ^b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF HELSINKI AND HELSINKI UNIVERSITY HOSPITAL   (Finland)

Author keywords

adalimumab; Crohn's disease; fecal markers; infliximab; long term outcome; ulcerative colitis

Indexed keywords

ADALIMUMAB; CALGRANULIN; FECAL CALPROTECTIN; INFLIXIMAB; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ASSESSMENT; COLONOSCOPY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE MARKER; ENZYME IMMUNOASSAY; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTIVE VALIDITY; PRIORITY JOURNAL; REMISSION; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; BIOLOGICAL MARKERS; CHILD; COLITIS, ULCERATIVE; CROHN DISEASE; DISEASE MANAGEMENT; FECES; FEMALE; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; REMISSION INDUCTION; ROC CURVE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84866548953     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.22863     Document Type: Article

References (34)

1. Harvey RF, Bradshaw JM,. A simple index of Crohn's-disease activity. Lancet. 1980; 1: 514.
2. Schroeder KW, Tremaine WJ, Ilstrup DM,. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Engl J Med. 1987; 317: 1625-1629.
3. Cellier C, Sahmoud T, Froguel E, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. Gut. 1994; 35: 231-235.
4. Biancone L, De Nigris F, Del Vecchio Blanco G, et al. Review article: monitoring the activity of Crohn's disease. Aliment Pharmacol Ther. 2002; 16 (Suppl 4): 29-33.
5. Arnott ID, Watts D, Ghosh S,. Review article: is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease? Aliment Pharmacol Ther. 2002; 16: 857-867.
6. Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc. 2006; 63: 433-442.
7. Rutgeerts P, Vermeire S, Van Assche G,. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut. 2007; 56: 453-455.
8. Froslie KF, Jahnsen J, Moum BA, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007; 133: 412-422.
9. D'Haens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology. 1999; 116: 1029-1034.
10. Baert F, Moortgat L, van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology. 2010; 138: 463-468.
11. Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc. 2006; 63: 433-442.
12. Rutgeerts P, D'Haens GR, Van Assche G, et al. Adalimumab induces and maintains mucosal healing in patients with moderate to severe ileocolonic Crohn's disease-first results of the EXTEND trial. Gastroenterology. 2009; 136: A116.
13. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353: 2462-2476.
14. Sipponen T, Savilahti E, Kolho K, et al. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis. 2008; 14: 40-46.
15. Røseth AG, Schmidt PN, Fagerhol MK,. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol. 1999; 34: 50-54.
16. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's Disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2010; 105: 162-169.
17. Tibble JA, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000; 119: 15-22.
18. Sipponen T, Kärkkäinen P, Savilahti E, et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol Ther. 2008; 28: 1221-1229.
19. Sipponen T, Savilahti E, Kolho KL, et al. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis. 2008; 14: 40-46.
20. Røseth AG, Aadland E, Grzyb K,. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol. 2004; 39: 1017-1020.
21. Sipponen T, Kärkkäinen P, Savilahti E, et al. Fecal calprotectin, lactoferrin and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis. 2008; 14: 1392-1398.
22. Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut. 2005; 54; 364-368.
23. Best WR,. Predicting the Crohn's disease activity index from the Harvey-Bradshaw index. Inflamm Bowel Dis. 2006; 12: 304-310.
24. D'Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007; 132: 763-786.
25. Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc. 2004; 60: 505-512.
26. Moskovitz DN, Daperno M, Van Assche G,. Defining and validating cut-offs for the Simple Endocopic Score for Crohn's Disease. Gastroenterology. 2007; 132: S1097.
27. D'Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007; 132: 763-786.
28. Kolho KL, Raivio T, Lindahl H, et al. Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease. Scand J Gastroenterol. 2006; 41: 720-725.
29. von Roon AC, Karamountzos L, Purkayastha S, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol. 2007; 102: 803-813.
30. Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis. 2009; 15: 1295-1301.
31. af Björkesten C-G, Nieminen U, Turunen U, et al. Endoscopic monitoring of infliximab therapy in Crohn's disease. Inflamm Bowel Dis. 2011; 17: 947-953.
32. D'Inca R, Dal Pont E, Di Leo V, et al. Can calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastroenterol. 2008; 103: 2007-2014.
33. Garcia-Sanchez V, Iglesias-Flores E, González R, et al. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis? J Crohn Colitis. 2010; 4: 144-152.
34. Guidi L, Marzo M, Felice C, et al. Fecal calprotectin values in inflammatory bowel disease patients after induction course of anti-TNF agents: correlation with the clinical response. Gastroenterology. 2010; 138: S686.